




The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Spyre Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 32% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	341,528
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,978
Liabilities, Non-Current	0
Other Assets	331
Other Compr. Net Income	350
Other Expenses	113,713
Other Liabilities	41,310
Other Net Income	-96,513
Other Revenues	886
Property and Equipment	0
Research and Development	89,504
Selling, General and Administrative Expense	39,946

Output Variable	Value in 1000 USD
Assets	341,859
Liabilities	73,288
Expenses	243,163
Revenues	886
Stockholders Equity	268,571
Net Income	-338,790
Comprehensive Net Income	-338,615
BaseVar	378,030
ECR before Limited Liability	119%
Economic Capital Ratio	245%